As of May 27
| +0.05 / +0.55%|
The 6 analysts offering 12-month price forecasts for Achillion Pharmaceuticals Inc have a median target of 8.50, with a high estimate of 16.00 and a low estimate of 7.00. The median estimate represents a -6.59% decrease from the last price of 9.10.
The current consensus among 7 polled investment analysts is to Hold stock in Achillion Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.